Entera Bio Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Entera Bio Ltd., a foreign private issuer headquartered in Jerusalem, Israel, for the month of January 2019. The filing, dated January 10, 2019, incorporates by reference a press release announcing a corporate governance update.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a board appointment and does not contain financial statements or performance data.
Material Changes
The material change disclosed in this filing is the appointment of Gerald M. Ostrov to the Company's Board of Directors. No financial or operational changes were reported in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding financial guidance, future outlook, risks, contingencies, or unusual items. The document is limited to the announcement of the new board member.
Key Facts for Investor Verification
- Entera Bio Ltd. appointed Gerald M. Ostrov to its Board of Directors on January 10, 2019.
- The filing is a Form 6-K reporting a press release and does not include financial results.
- Dr. Phillip Schwartz, Chief Executive Officer, signed the report on behalf of the registrant.